NMR heads into its July 29 first-quarter earnings release with options traders at their most defensive in at least a year, even as the stock notches a strong month.
The clearest tension is in the options market. The put/call ratio hit 2.03 on July 24 — the highest reading of the past 52 weeks and nearly two standard deviations above its 20-day average of 1.14. That level of downside protection demand is striking given that NMR has rallied 14% over the past month to $9.81, adding 4.4% in the past week alone. Investors appear to be buying into the rally while simultaneously hedging hard against the print.
The lending market tells a far calmer story. Borrow availability is extraordinarily loose — roughly 1,170% of short interest is covered by available shares, well above the 52-week floor of 193%, meaning there is no squeeze pressure in the lending pool whatsoever. Cost to borrow has also eased sharply, falling by nearly half over the past month to just 0.93% — a level that signals no meaningful crowding among short sellers. Short interest on the NYSE-listed ADR remains a small fraction of the float and has fallen roughly 24% over the past month, reinforcing that bearish conviction via the borrow market is low. The ORTEX short score of 30, while ticking up slightly in recent days, sits in the unremarkable range.
The analyst picture carries important caveats. JP Morgan upgraded NMR to Overweight from Neutral in March 2026 — the most meaningful recent analyst signal — but the broader consensus data is stale and the mean price target on record reflects data from 2020, making any target-versus-price comparison unreliable. What is current is the factor score picture: NMR's analyst recommendation differential ranks in the 99th percentile of the ORTEX universe, reflecting the JP Morgan upgrade against a backdrop of limited recent coverage activity. Institutionally, BlackRock added nearly 4.7 million shares as of June 30, lifting its stake to 9.4% of shares outstanding — the largest holder and an active adder. Insider activity has been token-sized, with director purchases totalling only a few thousand dollars at the ADR level in June.
Past prints have swung the stock sharply in both directions. The April 2026 report sent shares down 6.2% on the day and 5.6% over the following week. The May release produced a 2.5% gain on the day and a 5.3% five-day gain. The July 29 print will test whether the strong month-long rally — built on macro tailwinds for Japanese financials and the JP Morgan upgrade — can survive contact with the actual numbers, particularly on investment banking fees and trading volumes where recent notes flagged ongoing pressure.
See the live data behind this article on ORTEX.
Open NMR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
